These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2573989)

  • 61. Change of circulating thyroid autoantibody titers in Graves' hyperthyroidism after antithyroid drugs therapy.
    Lin HD; Tai FT; Chen HD; Lee SP; Chang FY; Wang GG; Tang KT; Lee JK
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Feb; 47(2):86-90. PubMed ID: 1705860
    [TBL] [Abstract][Full Text] [Related]  

  • 62. TSH-displacing activity versus TSH-binding inhibiting activity of immunoglobulins from patients with Graves' disease.
    Macchia E; Fenzi GF; Monzani F; Bartalena L; Lippi F; Aloisio V; Cupini C; Baschieri L; Pinchera A
    J Endocrinol Invest; 1983 Oct; 6(5):375-8. PubMed ID: 6141201
    [TBL] [Abstract][Full Text] [Related]  

  • 63. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
    Wallaschofski H; Kuwert T; Lohmann T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of separate determinants on the thyrotropin receptor reactive with Graves' thyroid-stimulating antibodies and with thyroid-stimulating blocking antibodies in idiopathic myxedema: these determinants have no homologous sequence on gonadotropin receptors.
    Kosugi S; Ban T; Akamizu T; Kohn LD
    Mol Endocrinol; 1992 Feb; 6(2):168-80. PubMed ID: 1349156
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Thyrotropin (TSH) receptor modulation by specific TSH receptor antibodies in Graves' disease.
    de Bruin TW; Bussemaker JK; Heidema J; Hermans J; van der Heide D
    J Clin Endocrinol Metab; 1988 Oct; 67(4):676-81. PubMed ID: 2901428
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Serum immunoglobulin G4 levels and Graves' disease phenotype.
    Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
    Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
    Bossowski A; Stasiak-Barmuta A; Urban M
    Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
    Baldini M; Castagnone D; Rivolta R; Meroni L; Pappalettera M; Cantalamessa L
    Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Partial characterization and clinical correlation of circulating human immunoglobulins directed against thyrotrophin binding sites in guinea pig fat cell membranes. Development of a direct enzyme immunoassay.
    Baker JR; Lukes YG; Smallridge RC; Berger M; Burman KD
    J Clin Invest; 1983 Oct; 72(4):1487-97. PubMed ID: 6138364
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease.
    Schleusener H; Schwander J; Fischer C; Holle R; Holl G; Badenhoop K; Hensen J; Finke R; Bogner U; Mayr WR
    Acta Endocrinol (Copenh); 1989 Jun; 120(6):689-701. PubMed ID: 2567102
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves' disease?
    Madec AM; Laurent MC; Lorcy Y; Le Guerrier AM; Rostagnat-Stefanutti A; Orgiazzi J; Allannic H
    Clin Endocrinol (Oxf); 1984 Sep; 21(3):247-55. PubMed ID: 6148163
    [TBL] [Abstract][Full Text] [Related]  

  • 73. TSH suppression combined with carbimazole for Graves' disease: effect on remission and relapse rates.
    Pujol P; Osman A; Grabar S; Daurès JP; Galtier-Dereure F; Boegner C; Baldet L; Raye R; Bringer J; Jaffiol C
    Clin Endocrinol (Oxf); 1998 May; 48(5):635-40. PubMed ID: 9666876
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Relationships between plasma thyrotropin receptor antibodies and lipid or lipoprotein parameters in Graves' disease.
    Rieu M; Revue E; Bonete R; Nunez S
    Eur J Endocrinol; 1996 Jul; 135(1):77-81. PubMed ID: 8765977
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Spin echo nuclear magnetic resonance studies on intact erythrocytes: changes in cellular metabolism as a consequence of carbimazole therapy.
    Reglinski J; Smith WE; Wilson R; Buchanan LM; McKillop JH; Thomson JA
    Clin Endocrinol (Oxf); 1992 Oct; 37(4):319-24. PubMed ID: 1362374
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
    Hardisty CA; Hanford L; Munro DS
    Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease.
    Wilson R; McKillop JH; Henderson N; Pearson DW; Thomson JA
    Clin Endocrinol (Oxf); 1986 Aug; 25(2):151-6. PubMed ID: 3491692
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Do HLA-DR-typing and measurement of TSH-receptor antibodies help in the prediction of the clinical course of Graves' thyrotoxicosis after antithyroid drug treatment?
    Schleusener H; Schwander J; Holl G; Badenhoop K; Hensen J; Finke R; Schernthaner G; Mayr WR; Kotulla P
    Acta Endocrinol Suppl (Copenh); 1987; 281():318-24. PubMed ID: 2441554
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evidence for carbimazole as an antioxidant?
    Wilson R; Buchanan L; Fraser WD; Jenkins C; Smith WE; Reglinski J; Thomson JA; McKillop JH
    Autoimmunity; 1998; 27(3):149-53. PubMed ID: 9609132
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Failure of the TRH test to predict the clinical course of patients in remission after antithyroid drug therapy for Graves' disease.
    Irvine WJ; Gray RS; Toft AD; Seth J; Cameron EH
    Acta Endocrinol (Copenh); 1979 Jan; 90(1):18-22. PubMed ID: 104514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.